Pneumococcal Vaccination Strategies in the Real World of Chronically Ill Patients

REFERENCES

1. 1.↵
   1. Immunization, vaccines and biologicals

   . WHO recommendations for routine immunization — summary tables. [Internet. Accessed November 26, 2015.] Available from: www.who.int/immunization/policy/immunization_tables/en/
2. 2.↵
   1. Bonten MJ,
   2. Huijts SM,
   3. Bolkenbaas M,
   4. Webber C,
   5. Patterson S,
   6. Gault S,
   7. et al.

   Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114–25.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. van Assen S,
   2. Elkayam O,
   3. Agmon-Levin N,
   4. Cervera R,
   5. Doran MF,
   6. Dougados M,
   7. et al.

   Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011;10:341–52.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Heijstek MW,
   2. Ott de Bruin LM,
   3. Bijl M,
   4. Borrow R,
   5. van der Klis F,
   6. Kone-Paut I,
   7. et al.

   EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704–12.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Silva CA,
   2. Aikawa NE,
   3. Bonfa E

   . Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol 2013;9:532–43.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Heijstek MW,
   2. Kamphuis S,
   3. Armbrust W,
   4. Swart J,
   5. Gorter S,
   6. de Vries LD,
   7. et al.

   Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013;309:2449–56.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Borte S,
   2. Liebert UG,
   3. Borte M,
   4. Sack U

   . Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology 2009;48:144–8.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Elkayam O,
   2. Paran D,
   3. Caspi D,
   4. Litinsky I,
   5. Yaron M,
   6. Charboneau D,
   7. et al.

   Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147–53.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Aikawa NE,
   2. Franca IL,
   3. Ribeiro AC,
   4. Sallum AM,
   5. Bonfa E,
   6. Silva CA

   . Short and longterm immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine 2015;33:604–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Farmaki E,
    2. Kanakoudi-Tsakalidou F,
    3. Spoulou V,
    4. Trachana M,
    5. Pratsidou-Gertsi P,
    6. Tritsoni M,
    7. et al.

    The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine 2010;28:5109–13.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Broyde A,
    2. Elkayam O,
    3. Caspi D,
    4. Levartosvki D,
    5. Paran D,
    6. Arad U,
    7. et al.

    The longterm efficacy of an anti-pneumococcal polysaccharide vaccine (PPSV23, Pneumovax) among autoimmune inflammatory rheumatic patients. J Rheumatol 2016;43:267–72.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Stoof SP,
    2. Heijstek MW,
    3. Sijssens KM,
    4. van der Klis F,
    5. Sanders EA,
    6. Teunis PF,
    7. et al.

    Kinetics of the longterm antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Ann Rheum Dis 2014;73:728–34.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Heijstek MW,
    2. van Gageldonk PG,
    3. Berbers GA,
    4. Wulffraat NM

    . Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis 2012;71:948–54.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Nguyen DL,
    2. Nguyen ET,
    3. Bechtold ML

    . Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci 2015;60:2446–53.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Rahier JF,
    2. Moutschen M,
    3. Van Gompel A,
    4. Van Ranst M,
    5. Louis E,
    6. Segaert S,
    7. et al.

    Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology 2010;49:1815–27.

    OpenUrlAbstract/FREE Full Text